How I give venetoclax + azacitidine to patients with AML
Vložit
- čas přidán 6. 09. 2024
- In this podcast, I discuss how I treat patients with with venetoclax plus azacitidine. I go over drug interactions and how I do antibiotic/antifungal prophylaxis. I also go over appropriate dose adjustments and timing of bone marrow biopsies.
“Papa’s Pod” is now available on Apple, Spotify and Google!
To view more my MedEd content visit my substack - aarongoodman.s...
About Aaron Goodman M.D.
Aaron Goodman M.D., also known as "Papa Heme," is a hematologist-oncologist based in San Diego, California. He has gained a significant following on social media platforms such as Twitter where he shares his expertise and knowledge on blood disorders and cancer with his followers.
Dr. Goodman uses social media to educate and raise awareness about hematology and oncology, and the impact these diseases can have on individuals and families. His content includes informative posts about specific blood disorders and cancers, updates on the latest research and clinical trials, and helpful resources for patients and caregivers.
One of Dr. Goodman's unique approaches to social media is his use of humor and relatable content to engage with his followers. He often shares personal anecdotes and stories, which not only educate but also provide a sense of empathy and connection with his audience.
Through his social media presence, Dr. Goodman has created a community of patients, caregivers, and healthcare professionals who are passionate about hematology and oncology. He has also used social media to advocate for patients' rights and to address issues related to healthcare disparities and accessibility.
Overall, Dr. Goodman's use of social media has allowed him to extend his reach beyond his clinical practice and make a positive impact on the wider community. His innovative approach to education and advocacy has helped to break down barriers and create a more inclusive and informed healthcare landscape.
Hey Papa! How about a video on Richters Transformation? Outcomes and approach to transplant if a person can make it that far.
I really need these back! Regards from Spain
I have read that it is under investigation for treatment of PCTL NOS and Transformed Mycosis Fungoides but not yet approved for those disorders.
What if they have blast reduction but don't achieve CRI after cycle 1, would you postpone cycle 2 start starting day 29 if neutropenic?
Do patients stay on Ven/aza indefinitely or do you stop when blasts are less than 5%. How long do they need to be on ven/aza?